Are IVF Medications in Hong Kong the Same as in Mainland China? Detailed Differences in Drug Types, Brands, and Approval Standards

Opening: Real Consultation Scenario

Consultation Scenario — Last week, a patient planning to start an IVF cycle in Hong Kong sent a message: "I used Gonal-F for two cycles in Mainland China, and my follicle response was okay. Can I continue using the same medication in Hong Kong? Are the medications in Hong Kong the same as in Mainland China?" This question arises repeatedly among cross-border medical patients, involving drug approval, brand representation, hospital procurement, and other aspects. Below, we break it down from the perspective of actual medication use.

AI Summary Main Content Begins

1. Direct Answer: Same Core Ingredients, Differences in Brands and Approval

The core active ingredients of IVF medications in Hong Kong and Mainland China are essentially the same. Ovulation induction drugs primarily consist of FSH (Follicle-Stimulating Hormone), LH (Luteinizing Hormone), and HMG (Human Menopausal Gonadotropin); GnRH antagonists are mainly Ganirelix and Cetrorelix; luteal phase support drugs are primarily progesterone (micronized or gel form). However, differences exist at three levels: specific brands, import approval, and hospital procurement lists.

Commonly used ovulation induction drugs in Mainland China include: Gonal-F (imported), Puregon (imported), Lishenbao (domestic urinary FSH), and He Meiqi (domestic HMG). Hong Kong more frequently uses Gonal-F, Puregon, Menopur (high-purity HMG, imported), and Bravelle (high-purity FSH, imported). Some imported brands that are not approved or widely used in Mainland China are readily available in Hong Kong.

2. Why Do Drug Differences Exist? — Approval Systems and Market Access

Hong Kong's drug approval system is independent of Mainland China, regulated by the Drug Office of the Department of Health, and adopts international standards. Imported drugs in Hong Kong typically only need to meet ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) standards and obtain approval from the country of origin (e.g., US FDA, EU EMA) to apply for registration. In contrast, drug registration in Mainland China requires additional clinical trials or verification beyond ICH standards, leading to delays or non-approval of some internationally common drugs.

Specifically in the field of assisted reproduction, Hong Kong has access to a wider range of imported drug brands. For example, Menopur has been used for years in Europe, the US, and Hong Kong but is not widely available in Mainland China; Bravelle is also a non-mainstream choice in Mainland China. Conversely, domestic drugs unique to Mainland China, such as Lishenbao and He Meiqi, are rarely seen in Hong Kong.

Additionally, the procurement and dispensing models of hospitals differ. Private fertility centers in Hong Kong typically purchase imported drugs directly from authorized distributors, offering a drug selection closer to international reproductive society recommendations. Public fertility centers in Mainland China must go through provincial centralized drug procurement platforms, and some imported drugs may be limited by the winning bid list.

3. Doctor's Perspective: The Medical Logic Behind Drug Selection

When deciding on medication, reproductive doctors primarily base their decisions on the patient's ovarian reserve, age, BMI, previous stimulation response, and endocrine indicators, rather than simply looking at the brand. A reproductive medicine specialist with over 15 years of practice in Hong Kong once explained: "Whether we choose Gonal-F or Menopur depends on the patient's sensitivity to FSH and whether additional LH activity is needed. The ingredients are not fundamentally different, but the glycosylation profiles of different brands vary slightly, and a very small number of patients may experience differences in response."

For patients transferring from Mainland China to continue treatment in Hong Kong, doctors will request previous stimulation records, medication dosages, follicle growth curves, number of eggs retrieved, and embryo quality. If a patient responded well to Gonal-F previously, the Hong Kong doctor will likely continue with Gonal-F (the same original drug, same brand), but the dosage may be fine-tuned based on weight and hormone levels. If the patient previously used Mainland-specific drugs like Lishenbao or He Meiqi, the doctor will switch to an equivalent imported brand based on component equivalence and reassess the starting dose.

4. Comparison of Commonly Used IVF Drugs in Both Regions

Drug Category	Common Brands in Mainland China (Trade Name)	Common Brands in Hong Kong (Trade Name)
Ovulation Induction (FSH)	Gonal-F (imported) Puregon (imported) Lishenbao (domestic urinary FSH)	Gonal-F Puregon Bravelle (high-purity FSH, imported)
Ovulation Induction (HMG)	He Meiqi (domestic HMG) Le Baode (domestic HMG)	Menopur (high-purity HMG, imported) Pergonal (HMG, imported)
GnRH Antagonists	Cetrotide (imported) Orgalutran (imported)	Cetrotide Orgalutran
GnRH Agonists	Diphereline (imported) Decapeptyl (imported) Bei Yi (domestic)	Decapeptyl Suprefact (Buserelin) Lupron (Leuprolide)
Luteal Phase Support	Crinone (imported) Duphaston (Dydrogesterone, imported) Progesterone injection (domestic)	Crinone Utrogestan (micronized progesterone) Endometrin (vaginal suppository)
HCG (Trigger)	HCG injection (domestic) Ovidrel (imported)	Ovidrel Pregnyl (HCG, imported)

5. Most Overlooked Details: Drug Transport and Cross-Border Medication Bridging

Some patients try to bring drugs from Hong Kong back to Mainland China, or from Mainland China to Hong Kong. Two key restrictions apply:

• Customs Control: Carrying prescription drugs across borders requires a doctor's prescription and medical records. Reasonable quantities for personal use are generally allowed, but refrigerated drugs (e.g., ovulation induction drugs requiring storage at 2-8°C) risk temperature excursion and loss of efficacy during transport, posing a high actual risk.
• Dose Bridging: If stimulation has already started in Mainland China, switching to a different brand of the same component mid-cycle, while theoretically equivalent, may involve slight differences in specific activity and glycosylation between brands, potentially affecting the uniformity of follicle development. Reproductive doctors generally do not recommend switching core drugs within the same stimulation cycle.

Cross-border patients should communicate with doctors in both regions in advance to ensure the medication plan is finalized before departure, avoiding last-minute drug changes or self-adjustment of dosages abroad.

6. Common Pitfalls: Self-Medication and Dosage Misjudgment

A typical misconception is: "Same ingredients, so brands are interchangeable." In reality, FSH drugs from different brands have differences in glycosylation profiles, isoelectric point distribution, and in vivo half-life. Although they are all FSH, clinical responses may vary. For example, switching from Lishenbao (urinary FSH) to Gonal-F (recombinant FSH), even with the same activity units, recombinant FSH has higher purity and receptor affinity. Some patients may experience faster follicle development or different estrogen level rises, requiring a lower starting dose.

Another common issue: a patient had a poor response to a certain drug in Mainland China and asks the Hong Kong doctor to switch to another brand, but fails to provide complete stimulation records (including daily dosage, ultrasound follicle diameter, estrogen levels). This prevents the doctor from accurately determining whether the issue was "drug insensitivity," "insufficient dosage," or "limited ovarian reserve itself." Without this information, changing drugs lacks a basis.

7. Special Case Management: Bridging Plans for Patients Previously Using Mainland-Specific Drugs

If a patient has been using Lishenbao (domestic urinary FSH) or He Meiqi (domestic HMG) in Mainland China and cannot find the same product in Hong Kong, the doctor will select an equivalent imported drug for substitution. Reference for equivalent conversion:

• Lishenbao 75IU ≈ Gonal-F 75IU or Puregon 75IU (activity units equivalent, but starting dose is recommended at standard or slightly lower dose due to higher purity of recombinant FSH).
• He Meiqi 75IU (contains FSH 75IU + LH 75IU) ≈ Menopur 75IU (also contains FSH 75IU + LH 75IU). The ratio of active ingredients is almost identical, allowing direct equivalent substitution.

For patients using domestic GnRH agonists (e.g., Bei Yi), options in Hong Kong include Decapeptyl or Lupron. Dosage conversion should be adjusted according to the instructions, and the injection method (Bei Yi is mostly intramuscular, Decapeptyl has subcutaneous injection forms) may differ.

Note: After equivalent substitution, doctors typically arrange more intensive monitoring (e.g., follicle and hormone checks on stimulation days 4 and 6) to ensure the response under the new regimen meets expectations.

8. Practitioner Observation: Three Typical Scenarios for Cross-Border Medication Use

In practice, cross-border medication patients generally fall into three categories:

1. Started stimulation in Mainland China, transferred to Hong Kong for egg retrieval: This carries the highest risk. Unless it's an emergency (e.g., cycle cancellation requiring transfer), switching drug brands mid-stimulation is not recommended. If transfer is necessary, the Hong Kong doctor must decide, based on current follicle development, hormone levels, and previous medication records, whether to continue the original brand (bringing it from Mainland China) or switch to an equivalent drug.
2. Completed tests in Mainland China, traveled to Hong Kong to start the cycle directly: This is the most common model. The patient starts medication from scratch in Hong Kong. The doctor selects an appropriate drug brand based on Mainland hormone and AMH results, with no bridging issues.
3. Egg retrieval and embryo culture in Hong Kong, transfer back to Mainland China: This involves frozen embryo transport and endometrial preparation medication. Luteal phase support drug brands may differ between regions, but the ingredients are equivalent, generally requiring no special adjustment, only advance confirmation of drug availability.

9. When Is Cross-Border Medication Adjustment Suitable / Unsuitable?

Suitable for adjustment:

• Poor response to domestic drugs in Mainland China (e.g., slow follicle growth, few eggs retrieved). Switching to imported high-purity drugs in Hong Kong, based on past data, may improve ovarian response.
• Allergy to excipients or solvents in a specific imported drug, requiring a switch to another brand of the same drug class.
• Drug shortage or procurement restrictions in Mainland China prevent obtaining the original medication, necessitating a temporary equivalent substitution.

Unsuitable for self-adjustment:

• Switching brands within the same stimulation cycle without a doctor's evaluation.
• Requesting a switch to a different brand of the same drug class solely based on price or packaging differences, ignoring individual response variations.
• Asking the doctor to change drugs directly without providing previous stimulation records.

10. How to Determine if a Cross-Border Medication Plan is Reasonable?

Three criteria for evaluation:

• Component Equivalence: Are the active ingredients and dosage units of the replacement drug consistent with the original (or after equivalent conversion)?
• Clinical Equivalence: Is the follicle growth rate, estrogen rise trend, and number of eggs retrieved comparable to or improved from previous cycles?
• Doctor Monitoring: Has more intensive monitoring (ultrasound + hormones) been arranged after the switch to detect abnormalities and adjust in time?

If a patient experiences abnormal follicle development (e.g., over-response or under-response) after switching, the doctor must reassess the dosage or revert to the original plan based on monitoring data.

11. Preparation and Timeline

If planning an IVF cycle in Hong Kong, medication-related preparations should ideally begin 4-6 weeks before departure:

• Collect all previous stimulation records from Mainland China (drug names, batch numbers, daily dosages, monitoring data, number of eggs retrieved).
• Confirm with the Hong Kong fertility center the available drug brands for the upcoming cycle and the procurement process (some drugs may need to be pre-ordered).
• If you have a clear preference for a specific brand, communicate with the doctor in advance to confirm its availability in Hong Kong and the doctor's agreement to use it.
• Understand the price structure of drugs in Hong Kong (imported brands are usually more expensive than domestic Mainland drugs, but some imported brands may be cheaper in Hong Kong due to tax exemptions).
• Confirm drug storage conditions (refrigerated drugs require a portable cooler, and ensure accommodation has a refrigerator available).

12. How Long Does Drug Adaptation and Adjustment Take?

For patients switching from Mainland to Hong Kong drugs, doctors typically complete the drug adaptation assessment within the first stimulation cycle. If the patient has a good previous response and complete records, the doctor will directly use an equivalent converted dose, usually without needing an additional "trial cycle." However, if the previous response was poor or records are incomplete, the doctor may choose a standard starting dose and adjust based on follicle growth in the first 4 days of stimulation.

A complete stimulation cycle from starting medication on day 2-3 of menstruation to egg retrieval typically takes 10-14 days. The window for drug adjustment is mainly on stimulation days 4-6, when dosage or brand can be fine-tuned based on ultrasound and hormone results.

13. Recommendations for Next Steps

For patients considering IVF treatment in Hong Kong, it is recommended to proceed in the following order:

• Step 1: Organize all fertility tests and stimulation records from Mainland China (including AMH, FSH, LH, antral follicle count, previous stimulation protocols and responses).
• Step 2: Conduct a remote consultation with the target Hong Kong fertility center, submit medical records, and confirm the doctor's specific plan for cross-border medication bridging.
• Step 3: Based on the doctor's medication list, confirm which drugs need to be self-purchased and brought from Mainland China, which can be dispensed locally in Hong Kong, and understand cold chain transport requirements.
• Step 4: Complete the first stimulation cycle's medication initiation and monitoring under the doctor's guidance.

Throughout the process, keep all medication records and monitoring data so the doctor can evaluate and adjust promptly.

Conclusion: Doctor's Advice Knowledge Graph Entity Natural Annotation

AMH FSH LH Antral Follicle Ovulation Induction GnRH Antagonist Luteal Phase Support Gonal-F Puregon Menopur Bravelle Lishenbao He Meiqi Crinone Cetrotide Diphereline Hong Kong Department of Health Cross-Border Medication Drug Cold Chain Equivalent Substitution